Liraglutide reduces plasma arginine vasopressin in healthy humans, modulating brain-kidney axis via synaptic protein phosphorylation and aquaporin 2.
Background
The brain-kidney axis plays a critical role in fluid and electrolyte homeostasis, primarily regulated by arginine vasopressin (AVP). While glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide are known to induce diuresis and natriuresis, their precise interaction with hormonal systems controlling fluid balance, particularly AVP, remains poorly understood. Understanding this interaction is crucial for elucidating the cardiovascular and renal benefits observed with GLP-1RAs, moving beyond their established glucose-lowering effects.
Study Design
Researchers conducted a single-center, open-label, before-and-after clinical study in 22 healthy human subjects to assess the impact of liraglutide on plasma AVP levels. Concurrently, an experimental investigation utilized rat pituitary glands for quantitative proteomic and phosphoproteomic analysis to detail time- and sex-dependent synaptic protein modifications. An in vitro AVP luciferase assay was developed to identify specific synaptic protein phosphosites influencing AVP release. Finally, posttranslational modifications of the AVP-regulated water channel aquaporin 2 were examined in rat kidneys.
Results
In the human clinical arm, liraglutide treatment significantly reduced plasma arginine vasopressin (AVP) levels in healthy individuals. This finding prompted deeper mechanistic exploration in preclinical models. Quantitative proteomic and phosphoproteomic analyses of rat pituitary glands revealed significant time- and sex-dependent modifications to synaptic proteins following liraglutide administration. These changes suggest a direct influence on neuronal signaling pathways involved in AVP regulation. The developed in vitro AVP luciferase assay successfully identified specific synaptic protein phosphosites that directly influence AVP release, further demonstrating liraglutide's impact on AVP secretion and highlighting sex-specific differences in this response.
Investigation of AVP downstream signaling pathways in the kidney unveiled crucial posttranslational changes to
aquaporin 2(AQP2), a key water channel regulated by AVP, indicating a direct renal effect. These findings collectively suggest that GLP-1RA modulation of AVP release, through both central and peripheral mechanisms, underpins observed cardiovascular and renal changes.
Key Findings
- Liraglutide significantly reduced plasma arginine vasopressin (AVP) levels in healthy human subjects.
- Liraglutide induced time- and sex-dependent modifications to synaptic proteins in rat pituitary glands.
- Specific synaptic protein phosphosites were identified that influence AVP release and mediate sex differences.
- Liraglutide treatment led to posttranslational changes in the AVP-regulated water channel aquaporin 2 in rat kidneys.
Why It Matters
This research provides a critical mechanistic link between liraglutide and fluid homeostasis, suggesting that its cardiovascular and renal benefits may stem from modulating AVP release and its downstream effects on aquaporin 2. For peptide users and clinicians, this implies that GLP-1RAs could be a valuable tool for managing conditions involving fluid retention or dysregulated AVP, such as certain forms of hypertension or kidney disease, beyond their metabolic effects. Understanding this brain-kidney axis modulation could lead to novel therapeutic strategies or refined GLP-1RA protocols for specific renal and cardiovascular indications. While a usable protocol is still distant, these findings lay the groundwork for future studies exploring liraglutide's potential in fluid balance disorders, potentially influencing how it's combined with other diuretics or antihypertensives.
liraglutide
arginine-vasopressin
avp
brain-kidney-axis
fluid-homeostasis
renal